MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Serum levels of miR-194 have been reported to predict prostate cancer recurrence after surgery, but its functional contributions to this disease have not been studied. Herein, it is demonstrated that miR-194 is a driver of prostate cancer metastasis. Prostate tissue levels of miR-194 were associated with disease aggressiveness and poor outcome. Ectopic delivery of miR-194 stimulated migration, invasion, and epithelial–mesenchymal transition in human prostate cancer cell lines, and stable overexpression of miR-194 enhanced metastasis of intravenous and intraprostatic tumor xenografts. Conversely, inhibition of miR-194 activity suppressed the invasive capacity of prostate cancer cell lines in vitro and in vivo. Mechanistic investigations identified the ubiquitin ligase suppressor of cytokine signaling 2 (SOCS2) as a direct, biologically relevant target of miR-194 in prostate cancer. Low levels of SOCS2 correlated strongly with disease recurrence and metastasis in clinical specimens. SOCS2 downregulation recapitulated miR-194–driven metastatic phenotypes, whereas overexpression of a nontargetable SOCS2 reduced miR-194–stimulated invasion. Targeting of SOCS2 by miR-194 resulted in derepression of the oncogenic kinases FLT3 and JAK2, leading to enhanced ERK and STAT3 signaling. Pharmacologic inhibition of ERK and JAK/STAT pathways reversed miR-194–driven phenotypes. The GATA2 transcription factor was identified as an upstream regulator of miR-194, consistent with a strong concordance between GATA2 and miR-194 levels in clinical specimens. Overall, these results offer new insights into the molecular mechanisms of metastatic progression in prostate cancer. Cancer Res; 77(4); 1021–34. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Combinatorial microRNA target predictions
Krek, A., Grün, D., Poy, M. N., Wolf, R., Rosenberg, L., Epstein, E. J., MacMenamin, P., da Piedade, I., Gunsalus, K. C., Stoffel, M., et al. (2005) · Nature Genetics · doi:10.1038/ng1536 · Cited by 4,603
MicroRNA targets in Drosophila
Enright, A. J., John, B., Gaul, U., Tuschl, T., Sander, C., & Marks, D. S. (2003) · Genome Biology · doi:10.1186/gb-2003-5-1-r1 · Cited by 3,597
The mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517 · cited 3×
“Data from the Grasso cohort (12), comprising 49 RP tumor samples, 27 metastases, and 12 normal prostate tissue samples, were obtained from the Gene Expression Omnibus (GEO; GSE35988).”
BackgroundMethodRegulatory networks defining EMT during cancer initiation and progression
Craene, B. D., & Berx, G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3447 · Cited by 2,487 · cited 12×
“50),MAP4K4 (39), the EMT-promoting transcription factor Bmi-1 (51), and the oncogenic transcription factor YAP1 (52).”
BackgroundInfluential
Cited by
Targeting oncogenic transcription factors: therapeutic implications of endogenous STAT inhibitors
Heppler, L. N., & Frank, D. A. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.10.004 · Cited by 74
Pei, T., Liu, C., Liu, T., Xiao, L., Luo, B., Tan, J., Li, X., Zhou, G., Duan, C., & Huang, W. (2018) · Endocrinology · doi:10.1210/en.2018-00374 · Cited by 73
A 25-gene classifier predicts overall survival in resectable pancreatic cancer
Birnbaum, D. J., Finetti, P., Lopresti, A., Gilabert, M., Poizat, F., Raoul, J.-L., Delpero, J.-R., Moutardier, V., Birnbaum, D., Mamessier, E., et al. (2017) · BMC Medicine · doi:10.1186/s12916-017-0936-z · Cited by 51
Das, R., Sjöström, M., Shrestha, R., Yogodzinski, C., Egusa, E. A., Chesner, L. N., Chen, W. S., Chou, J., Dang, D. K., Swinderman, J. T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24919-7 · Cited by 38
Self-citation
Metadata
- Authors
- Das, R., Gregory, P. A., Fernandes, R. C., Denis, I., Wang, Q., Townley, S. L., Zhao, S. G., Hanson, A. R., Pickering, M. A., Armstrong, H. K., Lokman, N. A., Ebrahimie, E., Davicioni, E., Jenkins, R. B., Karnes, R. J., Ross, A. E., Den, R. B., Klein, E. A., Chi, K. N., Ramshaw, H. S., Williams, E. D., Zoubeidi, A., Goodall, G. J., Feng, F. Y., Butler, L. M., Tilley, W. D., & Selth, L. A.
- Venue
- Cancer Research
- Published
- 2017-02-14
- Volume
- 77
- Issue
- 4
- Pages
- 1021-1034
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2565706366
- Cited by
- 117
- References
- 4
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2. https://app.cochat.ai/papers/10.1158/0008-5472.can-16-2529
- The paper
- Das, R., Gregory, P. A., Fernandes, R. C., Denis, I., Wang, Q., Townley, S. L., Zhao, S. G., Hanson, A. R., Pickering, M. A., Armstrong, H. K., Lokman, N. A., Ebrahimie, E., Davicioni, E., Jenkins, R. B., Karnes, R. J., Ross, A. E., Den, R. B., Klein, E. A., Chi, K. N., . . . Selth, L. A. (2017). MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2. Cancer Research. https://doi.org/10.1158/0008-5472.can-16-2529
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.